Novo Nordisk's (NVO) Victoza Returns More Promising Results Than Lilly's (LLY)/Amylin's (AMLN) Byetta
More News related to AMLN
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
- FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
- Unusual 11 Mid-Day Movers 11/02: HGSI, EAC, IUSA, VRTX Higher; CIT, YRCW, GTXI, CPF Lower
- Hapoalim Securities Upgrades Amylin (AMLN) to Hold; Two Important Milestones Achieved
More News related to LLY
- Award-winning Diabetes Documentary to Make World TV Premiere on Sundance Channel on World Diabetes Day
- Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018
- Oncology On Canvas(SM) Launches 2010 Art Competition for Individuals Touched by Cancer
- Trading Outlook for Avanir Pharmaceuticals Inc. Issued by InvestorSoup.com
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
More News related to NVO
- Novo Nordisk is Changing Possibilities in Hemophilia
- New Study Finds Significant Inconsistency With How Diabetes Quality of Care is Measured
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
- Trading Outlook for Generex Biotechnologies Corp. Issued by InvestorSoup.com
- Novo Nordisk Wins Design Award for NovoTwist(TM) Needle
More News related to Corporate News
- The Great Stock Hope (aka AIG) Gets a Lifeline
- Activision Blizzard's (ATVI) New "Call of Duty" Has Gamers Buzzing, But Stock Flat
- Energy Conversion Devices (ENER) Shares Continue Lower as JPMorgan, Citi Downgrade
- Moody's Suggests AIG (AIG) Could Repay the U.S.
- Buffett's Berkshire To Sell 9.6M Share Stake in Union Pacific (UNP) and 1.9M Share Stake In Norfolk Southern (NSC)
.jpg)
CNBC's Mike Huckman is reporting that a study comparing Novo Nordisk's (NYSE: NVO) Victoza and Eli Lilly's (NYSE: LLY)/Amylin's (Nasdaq: AMLN) Byetta returned better results for the Novo drug.
Novo's Victoza lowered patients blood sugar levels by 1.1%. During the study, 54% of patients taking Victoza reached their blood sugar level goal, while only 43% of patients taking Byetta achieved their goal. Also, patients taking Novo's product lost 7 pounds, compared to Byetta's 6.4 pounds lost.
Related Categories
Corporate NewsTrader Talk
Stocks Mentioned
+0.07
-0.07Comments
Victoza Vs Byetta
one study, doesnt mean anything. I have been on Byetta for 3 years, my glucose control is excellent
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
Victoza vs Byetta
Len B on Jul 23, 2009 03:37 PMI was moved on to Byetta from insulin in 2008 for a period of 9 months. Everything was fine for 7 months and I lost 42 pounds in weight and my glucoze control was excellent. Unfortunately, after 7 months my glucoze levels increased dramatically and my weight started to increase once again and after taking Byetta for 9 months I had to go back to insulin once again and my weight has increased to a higher level than it was when I started Byetta.although my glucoze levels have once again come under control. I have today been introduced to Victoza by my diabetic consultant and I hope to be accepted to receive this new product. I believe that the more people that are able to try these new items the better and more accurate studies will become. Who knows, with us being fortunate enough to try these new products one day there will be total control for all!